SHMT2 and ovarian cancer: Expression of SHMT2 was further analyzed using 24 cisplatin-sensitive and 12 cisplatin-resistant ovarian cancer tissues and confirmed the downregulation of SHMT2 in cisplatin-resistant ovarian cancer tissues (Fig. 1B).